*Important notice: This news reports on an unedited version of an accepted paper and is awaiting final editing. Therefore, the paper should not be regarded as conclusive or treated as established information.
A new laser-based mass spectrometry method has mapped drug-target complexes in intact biological tissues at 100 μm spatial resolution and measured target engagement of up to 78% in disease-relevant brain regions. The researchers' findings were published in Communications Chemistry.
Study: Intact protein mass spectrometry imaging at isotopic resolution enables assessment of covalent drug candidates. Image Credit: Alexander Supertramp/Shutterstock.com
By optimizing laser desorption and isotopic resolution, this methodology enabled researchers to track the spatial distribution of covalently bound drugs and their protein targets. This capability provides a way to assess where drug candidates interact with their targets during therapeutic development, addressing the challenges posed by covalent drugs that form permanent bonds with specific target proteins.
Why Is Covalent Drug Measurement Challenging?
Early pharmaceutical development requires scientists to determine where a drug interacts with its target. Covalent drugs form permanent bonds
with specific target proteins, which can provide pharmacological benefits but also create challenges for measuring these interactions in vivo. Conventional methods can quantify drug-target binding but often destroy the tissue during analysis, making it difficult to determine where the interactions occurred.
Laser-based imaging methods, such as matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI), preserve spatial information. However, detecting large, intact drug-protein complexes remains difficult due to mass limitations and signal interference.
Further improvements in laser desorption and mass resolution are essential to successfully map these complexes within biological tissues.
Methodological Advances in High-Resolution Spectrometry
To enhance the detection of large protein complexes, the researchers optimized Fourier-transform ion cyclotron resonance mass spectrometry (FTICR MS) coupled with MALDI. The goal was to extend the instrument’s upper mass range to detect intact proteins approaching 17 kDa. Parameters such as funnel radiofrequency amplitude and collision cell settings were adjusted to improve the detection of high-mass ions in tissues.
Download a free copy of this page here!
The study focused on the covalent drug candidate S-XL6, which targets superoxide dismutase 1 (SOD1) in a familial amyotrophic lateral sclerosis (fALS) model. The compound was administered to genetically modified mice with fluorescently labeled motor neurons. Before mass spectrometry imaging, fluorescence microscopy was performed using a 507 nm green fluorescence filter and a 10× objective to visualize relevant neurological regions.
Custom software was developed in R to process the imaging data using an isotopologue aggregation technique. The 10 most abundant isotopologues for each protein form were averaged to reduce background noise and separate overlapping signals. Mass spectrometry images were acquired at a spatial resolution of 100 μm and compared with fluorescence images, allowing the mass signals to be associated with specific anatomical structures.
Assessment of Target Engagement in Vivo
The optimized instrument produced spatial maps of target engagement for S-XL6, achieving a target engagement of up to 78% across the examined brain cross-sections. This measurement utilized a ratiometric imaging approach that compared the signal intensities of unmodified and modified protein forms within each pixel, improving the contrast between regions with different levels of target engagement.
Compared to standard time-of-flight mass spectrometry, the optimized Fourier-transform method produced a 40-fold higher signal-to-noise ratio for drug-protein complexes. Isotopic resolution minimized interference from signals, such as potassium adducts associated with the unmodified target protein. The distribution of engaged targets was consistent across the anatomical regions and corresponded with areas identified by fluorescence imaging.
The imaging data also provided insights into blood-brain barrier penetration. Intact hemoglobin subunits remained localized within blood vessels, while S-XL6 cross-linked protein complexes were distributed throughout the brain parenchyma. This spatial distribution indicated that S-XL6 successfully crossed the blood-brain barrier and reached target proteins within brain tissue.
Implications for Preclinical Drug Development
The combination of laser desorption and high-resolution mass spectrometry offers a robust method for the preclinical evaluation of covalent therapeutics. By integrating chemical measurements with spatial mapping, this approach can effectively measure drug exposure, target engagement, and tissue distribution within a single experiment.
This capability is particularly useful in research on neurodegenerative diseases, where understanding the location of drug activity within vulnerable tissues is critical. Mapping whether a therapeutic reaches specific brain regions could provide valuable information for evaluating drug distribution and target engagement during early-stage development.
Future Directions in Target-Specific Therapeutics
Overall, the optimized laser desorption mass spectrometry imaging method significantly enhances the analysis of covalent drug-protein complexes in tissue. Higher isotopic resolution and an expanded mass range for intact proteins enable spatial mapping of these complexes. The study found that S-XL6 crossed the blood-brain barrier and reached disease-relevant regions, achieving an average target engagement of 78%.
Future work could apply these data-processing methods to other drug targets and biological tissues. Expanding this research to additional therapeutic candidates could yield further insights into drug distribution and target engagement during preclinical development.
Journal Reference
Brahme, R.R., et al. (2026). Intact protein mass spectrometry imaging at isotopic resolution enables assessment of covalent drug candidates. Communications Chemistry. DOI: 10.1038/s42004-026-02180-7, https://www.nature.com/articles/s42004-026-02180-7.
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.